Transcriptomic analysis reveals high ITGB1 expression as a predictor for poor prognosis of pancreatic cancer.
Autorzy:
Iwatate Y; Division of Hepato-Biliary-Pancreatic Surgery, Chiba Cancer Center, Chiba, Japan. Yokota H; Department of Diagnostic Radiology and Radiation Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan. Hoshino I; Division of Gastroenterological Surgery, Chiba Cancer Center, Chiba, Japan. Ishige F; Division of Hepato-Biliary-Pancreatic Surgery, Chiba Cancer Center, Chiba, Japan. Kuwayama N; Division of Gastroenterological Surgery, Chiba Cancer Center, Chiba, Japan. Itami M; Division of Clinical Pathology, Chiba Cancer Center, Chiba, Japan. Mori Y; Graduate School of Engineering, Faculty of Engineering, Chiba University, Chiba, Japan. Chiba S; Division of Hepato-Biliary-Pancreatic Surgery, Chiba Cancer Center, Chiba, Japan. Arimitsu H; Division of Hepato-Biliary-Pancreatic Surgery, Chiba Cancer Center, Chiba, Japan. Yanagibashi H; Division of Hepato-Biliary-Pancreatic Surgery, Chiba Cancer Center, Chiba, Japan. Takayama W; Division of Hepato-Biliary-Pancreatic Surgery, Chiba Cancer Center, Chiba, Japan. Uno T; Department of Diagnostic Radiology and Radiation Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan. Lin J; Laboratory of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba Cancer Center, Chiba, Japan. Nakamura Y; Laboratory of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba Cancer Center, Chiba, Japan. Tatsumi Y; Laboratory of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba Cancer Center, Chiba, Japan. ShimozatoO; Laboratory of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba Cancer Center, Chiba, Japan. Nagase H; Laboratory of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba Cancer Center, Chiba, Japan.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2022 Jun 01; Vol. 17 (6), pp. e0268630. Date of Electronic Publication: 2022 Jun 01 (Print Publication: 2022).
Depletion of runt-related transcription factor 2 (RUNX2) enhances SAHA sensitivity of p53-mutated pancreatic cancer cells through the regulation of mutant p53 and TAp63.
Autorzy:
Ogata T; Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, Chiba, Japan. Nakamura M; Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, Chiba, Japan. Sang M; Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, Chiba, Japan.; Department of Regenerative Medicine, Graduate School of Medicine, University of Toyama, Toyama, Japan. Yoda H; Laboratory of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba, Japan. Hiraoka K; Laboratory of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba, Japan. Yin D; Research Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P.R. China. Sang M; Research Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P.R. China. ShimozatoO; Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, Chiba, Japan. Ozaki T; Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, Chiba, Japan.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2017 Jul 03; Vol. 12 (7), pp. e0179884. Date of Electronic Publication: 2017 Jul 03 (Print Publication: 2017).
Administration of DNA Encoding the Interleukin-27 Gene Augments Antitumour Responses through Non-adaptive Immunity.
Autorzy:
Li Q; Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chuo-ku, Chiba, Japan.; Department of Immunology, Hebei Medical University, Shijiazhuang, China.; Cell Therapy Center, The 1st Hospital of Hebei Medical University, Shijiazhuang, China.; Department of Molecular Biology and Oncology, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba, Japan. Sato A; Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chuo-ku, Chiba, Japan.; Department of Molecular Biology and Oncology, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba, Japan.; Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba, Japan. ShimozatoO; Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chuo-ku, Chiba, Japan. Shingyoji M; Department of Thoracic Diseases, Chiba Cancer Center, Chuo-ku, Chiba, Japan. Tada Y; Department of Respirology, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba, Japan. Tatsumi K; Department of Respirology, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba, Japan. Shimada H; Department of Surgery, School of Medicine, Toho University, Tokyo, Japan. Hiroshima K; Department of Pathology, Tokyo Women's Medical University Yachiyo Medical Center, Owada-Shinden, Yachiyo, Japan. Tagawa M; Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chuo-ku, Chiba, Japan.; Department of Molecular Biology and Oncology, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba, Japan.
Receptor-type protein tyrosine phosphatase κ directly dephosphorylates CD133 and regulates downstream AKT activation.
Autorzy:
ShimozatoO; Division of Biochemistry and Molecular Carcinogenesis, Chiba Cancer Center Research Institute, Chiba, Japan. Waraya M; Division of Biochemistry and Molecular Carcinogenesis, Chiba Cancer Center Research Institute, Chiba, Japan. Nakashima K; Division of Biochemistry and Molecular Carcinogenesis, Chiba Cancer Center Research Institute, Chiba, Japan. Souda H; Department of Gastrointestinal Surgery, Chiba Cancer Center Hospital, Chiba, Japan. Takiguchi N; Department of Gastrointestinal Surgery, Chiba Cancer Center Hospital, Chiba, Japan. Yamamoto H; Department of Gastrointestinal Surgery, Chiba Cancer Center Hospital, Chiba, Japan. Takenobu H; Division of Biochemistry and Molecular Carcinogenesis, Chiba Cancer Center Research Institute, Chiba, Japan. Uehara H; Division of Biochemistry and Molecular Carcinogenesis, Chiba Cancer Center Research Institute, Chiba, Japan. Ikeda E; Division of Biochemistry and Molecular Carcinogenesis, Chiba Cancer Center Research Institute, Chiba, Japan. Matsushita S; Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, Chiba, Japan. Kubo N; Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, Chiba, Japan. Nakagawara A; Division of Biochemistry and Innovative Cancer Therapeutics, Chiba Cancer Center Research Institute, Chiba, Japan. Ozaki T; Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, Chiba, Japan. Kamijo T; 1] Division of Biochemistry and Molecular Carcinogenesis, Chiba Cancer Center Research Institute, Chiba, Japan [2] Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan.
Pokaż więcej
Źródło:
Oncogene [Oncogene] 2015 Apr 09; Vol. 34 (15), pp. 1949-60. Date of Electronic Publication: 2014 Jun 02.
Fas ligand DNA enhances a vaccination effect by coadministered DNA encoding a tumor antigen through augmenting production of antibody against the tumor antigen.
Autorzy:
Zhong B; Department of Hematology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050035, China ; Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan. Ma G; Department of Hematology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050035, China. Sato A; Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan ; Department of Molecular Biology and Oncology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan. ShimozatoO; Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan ; Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan. Liu H; Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan. Li Q; Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan ; Department of Molecular Biology and Oncology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan ; Department of Immunology, Hebei Medical University, Shijiazhuang 050017, China ; Cell Therapy Center, 1st Hospital of Hebei Medical University, Shijiazhuang 050031, China. Shingyoji M; Department of Thoracic Diseases, Chiba Cancer Center, Chiba 260-8717, Japan. Tada Y; Department of Respirology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan. Tatsumi K; Department of Respirology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan. Shimada H; Department of Surgery, School of Medicine, Toho University, Tokyo 143-8541, Japan. Hiroshima K; Department of Pathology, Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo 276-8524, Japan. Tagawa M; Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan ; Department of Molecular Biology and Oncology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
Pokaż więcej
Źródło:
Journal of immunology research [J Immunol Res] 2015; Vol. 2015, pp. 743828. Date of Electronic Publication: 2015 Feb 18.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies